MedTrace Logo

TSI and Its Relationship With Graves' Disease Relapse

NCT05713097 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 352

Last updated 2023-02-06

No results posted yet for this study

Summary

The goal of this observational study is to determine the role of TSI, as well as clinical signs and thyroid function tests in predicting Graves' disease (GD) relapse after withdrawing anti thyroid drug (ATD). The main questions it aims to answer are:

1. To investigate the serum TSI concentration in patients with GD undergoing maintenance-dose ATD.
2. To determine an optimal cut-off of TSI level for predicting GD relapse.
3. To determine the role of TSI in predicting Graves' disease relapse after withdrawing ATD.

Conditions

  • Graves Disease
  • Immunoglobulin
  • Anti-Thyroid Antibodies Disorder

Interventions

DIAGNOSTIC_TEST

TSI

TSI was measured several times during the course of treatment when planning to stop medication (at the discretion of the attending physician).

Sponsors & Collaborators

  • University of Medicine and Pharmacy at Ho Chi Minh City

    lead OTHER

Principal Investigators

  • Vu Nhat Phong Nguyen, MD · University of Medecine and Pharmacy at Ho Chi Minh City

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-02
Primary Completion
2022-08-31
Completion
2022-08-31

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05713097 on ClinicalTrials.gov